In agreement with other reports, the authors also showed that GCS-100, an antagonist of Gal-3, induced cancer cell death [190,191,192], boosted tumor-infiltrating T lymphocyte secretion of IFN-gamma [143], and increased prostate cancer sensitivity to cisplatin [193]. This evidence concerns the gene LGALS3 and prostate cancer.